Melphalan Sun Pharmaceutical Industries Europe (Melphalan)

Melphalan belongs to the alkylating‑agent class. It binds covalently to DNA, forming cross‑links that block replication and transcription. This DNA damage triggers cell‑cycle arrest and programmed cell death, especially in rapidly dividing cancer cells, while sparing most normal tissues.

The dose of melphalan is individualized by the prescribing physician based on factors such as the specific cancer type, disease stage, patient weight or body surface area, renal and hepatic function, and prior treatment history. No fixed dosing schedule is provided here.

Melphalan is classified as contraindicated in pregnancy and breastfeeding because it can cross the placenta and be excreted in breast milk, posing a risk to the fetus or infant. Use is only considered if the potential benefit outweighs the known risks, and only under specialist guidance.

To request Melphalan Sun Pharmaceutical, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and import documentation.

Melphalan shares the core DNA‑cross‑linking mechanism of other alkylating agents but differs in its pharmacokinetic profile and approved indications. Compared with cyclophosphamide, melphalan is often preferred for high‑dose regimens in multiple myeloma and certain solid tumours, while it may have a higher risk of specific toxicities such as secondary malignancies.

Melphalan for intravenous use should be stored at ambient temperature, below 25 °C, in its original packaging. The container should be kept protected from light, moisture and extreme temperature fluctuations to maintain product stability.

Melphalan is administered intravenously by a qualified healthcare professional. The infusion is typically given over a defined period, often as a short‑term infusion or as part of a high‑dose protocol, depending on the treatment plan established by the oncologist.

The most serious risks include secondary malignancies, severe infections due to profound myelosuppression, and organ‑specific toxicities such as pulmonary fibrosis or renal failure. Patients should be closely monitored for signs of infection, respiratory distress, and changes in kidney function throughout treatment.

Melphalan is contraindicated in individuals with known hypersensitivity to the drug, in pregnant or breastfeeding women unless absolutely necessary, and in patients with severe uncontrolled infections or significant organ dysfunction that would increase toxicity risk. Final eligibility is determined by the treating physician.